(Total Views: 652)
Posted On: 05/20/2019 8:36:52 PM
Post# of 155267
Science continues to amaze, now it would seem the risk associated with financing has been/is being resolved?
some quick updates from the CC:
1) Non-binding term sheet for direct investment in Cytodyn for 20 M, + addition 10 M for joint-venture in China with Chinese entity. (months away)
2) Mid-tier pharma company in US explore TNBC, GVHD and NASH potential partnerships (Q4 2019)
3) Big-pharma discussions regarding monotherapy HIV
4) Specific commercialization pharma company has provided term-sheet w/upfront cash, with milestones related to HIV and GVHD
5) Prognostic test for Prostate cancer, will be receiving term sheet very soon
6) Samsung participation in potential capital investment in Cytodyn
7) Discussion with various companies for potential licensing agreements
.
**NO MORE DILUTION FINANCING**
**Tender offer with potential for 50 M**
**Cleaning up the balance sheet for bigger funds to join in**
some quick updates from the CC:
1) Non-binding term sheet for direct investment in Cytodyn for 20 M, + addition 10 M for joint-venture in China with Chinese entity. (months away)
2) Mid-tier pharma company in US explore TNBC, GVHD and NASH potential partnerships (Q4 2019)
3) Big-pharma discussions regarding monotherapy HIV
4) Specific commercialization pharma company has provided term-sheet w/upfront cash, with milestones related to HIV and GVHD
5) Prognostic test for Prostate cancer, will be receiving term sheet very soon
6) Samsung participation in potential capital investment in Cytodyn
7) Discussion with various companies for potential licensing agreements
.
**NO MORE DILUTION FINANCING**
**Tender offer with potential for 50 M**
**Cleaning up the balance sheet for bigger funds to join in**
(3)
(0)
